Overview

• The Elkton facility spans about 400,000 square feet and is slated to support more than 500 full-time roles plus roughly 8,000 construction jobs.
• Merck said the site will expand U.S. output of vaccines and critical medicines, including active pharmaceutical ingredients and new small‑molecule manufacturing and testing capacity.
• The company outlined three additional 2025 projects in North Carolina, Delaware and Kansas, bringing this year’s announced U.S. commitments to about $6 billion.
• Across the broader program, Merck projects more than 48,000 construction jobs by 2029, with most construction finishing by 2028, manufacturing starting in 2029 and supply operations beginning in 2030.
• Executives said they are in dialogue with the Trump administration on policy as the White House presses for domestic drug production and weighs tariffs tied to where medicines are made.